RT @DrDeborahFisher: Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life HRQoL in Oncology. Systematic revi…
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
This @JAMAInternalMed paper on lack of correlation between PFS and HRQOL should give all a pause into which points are critical in #Clinicaltrials & it’s another evidence on how critical #PROs are. CC @EthanBasch1 https://t.co/9p3TC3cFHx
How strongly is progression-free survival (PFS) associated with health-related quality of life (HRQoL) in studies of cancer treatments? Imaginan la respuesta? https://t.co/KV3LcchIAM
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
This is a must read. Kudo's to the authors for a terrific and necessary paper. PFS is a misleading endpoint that means little to patients. There is too much involved in cancer research (not only money, but also hope) to accept this. https://t.co/aOsxar2nrw
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @DrAEvens: Important paper/analyses in @JAMA_current re: the non-correlation of PFS with #HRQL in #cancer. https://t.co/O1wxgEibWm
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
Important paper/analyses in @JAMA_current re: the non-correlation of PFS with #HRQL in #cancer. https://t.co/O1wxgEibWm
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology https://t.co/Pz6THS9Ozo https://t.co/4FEMiH1pVI
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
Une revue systématique internationale montre qu' il n' y a pas d' association entre la survie sans progression et la qualité de vie perçue. Cette association est postulée pour légitimer l'utilisation de la survie sans prog comme critère pr octroyer l' AM
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
Message from this study is worth pondering up on much more than that of most individual RCTs
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
This is a common theme in @BeMedSavvy.
RT @m_waligora: Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between…
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
Finally out. Our meta-research on surrogate endpoints in cancer trials: We failed to find a significant association between #PFS and #HRQoL in #cancer clinical trials. @oncology_bg @VPplenarysesh https://t.co/poDP71rexu
RT @oh_henry: Important. https://t.co/WUXGGzkUFA
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
Important. https://t.co/WUXGGzkUFA
Surrogate endpoints are one of the major hobgoblins of clinical epidemiology, as people like Ioannidis & @VPplenarysesh have argued repeatedly. Also a ripe tool for manipulation & shenanigans by commercial industries, as history shows.
RT @geri_doc: Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to…
Progression-Free Survival (PFS) is a very common outcome measure in Oncology Important analysis shows little relationship to quality of life+well being. PFS is vastly over rated outcome measure Should rarely be used to justify new therapeutic agents #hpm
RT @fauber_mjs: Confirming our 2014 story https://t.co/sp9ehBRqnO , a new study found that quality of life benefits were not linked to a co…
Confirming our 2014 story https://t.co/sp9ehBRqnO , a new study found that quality of life benefits were not linked to a common cancer drug approval measure https://t.co/ENrGWqdXuP We also showed a lack of proven survival.